504 related articles for article (PubMed ID: 9695737)
1. Short chain fatty acids inhibit human (SW1116) colon cancer cell invasion by reducing urokinase plasminogen activator activity and stimulating TIMP-1 and TIMP-2 activities, rather than via MMP modulation.
Emenaker NJ; Basson MD
J Surg Res; 1998 Apr; 76(1):41-6. PubMed ID: 9695737
[TBL] [Abstract][Full Text] [Related]
2. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
3. Short-chain fatty acids inhibit invasive human colon cancer by modulating uPA, TIMP-1, TIMP-2, mutant p53, Bcl-2, Bax, p21 and PCNA protein expression in an in vitro cell culture model.
Emenaker NJ; Calaf GM; Cox D; Basson MD; Qureshi N
J Nutr; 2001 Nov; 131(11 Suppl):3041S-6S. PubMed ID: 11694645
[TBL] [Abstract][Full Text] [Related]
4. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential.
Nishikawa A; Iwasaki M; Akutagawa N; Manase K; Yamashita S; Endo T; Kudo R
Gynecol Oncol; 2000 Nov; 79(2):256-63. PubMed ID: 11063654
[TBL] [Abstract][Full Text] [Related]
5. Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
Knappe UJ; Hagel C; Lisboa BW; Wilczak W; Lüdecke DK; Saeger W
Acta Neuropathol; 2003 Nov; 106(5):471-8. PubMed ID: 12904990
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells.
Pei XH; Nakanishi Y; Takayama K; Bai F; Hara N
Br J Cancer; 1999 Jan; 79(1):40-6. PubMed ID: 10408691
[TBL] [Abstract][Full Text] [Related]
7. Association of a high activity of matrix metalloproteinase-9 to low levels of tissue inhibitors of metalloproteinase-1 and -3 in human hepatitis B-viral hepatoma cells.
Kim JR; Kim CH
Int J Biochem Cell Biol; 2004 Nov; 36(11):2293-306. PubMed ID: 15313474
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species.
Park MJ; Lee JY; Kwak HJ; Park CM; Lee HC; Woo SH; Jin HO; Han CJ; An S; Lee SH; Chung HY; Park IC; Hong SI; Rhee CH
J Cell Biochem; 2005 Aug; 95(5):955-69. PubMed ID: 15962302
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line.
Lu KV; Jong KA; Rajasekaran AK; Cloughesy TF; Mischel PS
Lab Invest; 2004 Jan; 84(1):8-20. PubMed ID: 14631378
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1.
Ramer R; Hinz B
J Natl Cancer Inst; 2008 Jan; 100(1):59-69. PubMed ID: 18159069
[TBL] [Abstract][Full Text] [Related]
11. Mouse trophoblastic cell lines: II--Relationship between invasive potential and proteases.
Sharma RK
In Vivo; 1998; 12(2):209-17. PubMed ID: 9627804
[TBL] [Abstract][Full Text] [Related]
12. Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system.
Jo Y; Yeon J; Kim HJ; Lee ST
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):511-9. PubMed ID: 10642509
[TBL] [Abstract][Full Text] [Related]
13. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells.
Rosenthal EL; Johnson TM; Allen ED; Apel IJ; Punturieri A; Weiss SJ
Cancer Res; 1998 Nov; 58(22):5221-30. PubMed ID: 9823336
[TBL] [Abstract][Full Text] [Related]
14. Brain-derived neurotrophic factor inducing angiogenesis through modulation of matrix-degrading proteases.
Sun CY; Hu Y; Wang HF; He WJ; Wang YD; Wu T
Chin Med J (Engl); 2006 Apr; 119(7):589-95. PubMed ID: 16620701
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
Baker EA; Bergin FG; Leaper DJ
Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
[TBL] [Abstract][Full Text] [Related]
16. Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-alpha receptors in a human colon adenocarcinoma (Colo 205) cell line.
Lombard MA; Wallace TL; Kubicek MF; Petzold GL; Mitchell MA; Hendges SK; Wilks JW
Cancer Res; 1998 Sep; 58(17):4001-7. PubMed ID: 9731514
[TBL] [Abstract][Full Text] [Related]
17. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
18. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
19. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue.
Brehmer B; Biesterfeld S; Jakse G
Prostate Cancer Prostatic Dis; 2003; 6(3):217-22. PubMed ID: 12970724
[TBL] [Abstract][Full Text] [Related]
20. Increased TIMP/MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation.
Badier-Commander C; Verbeuren T; Lebard C; Michel JB; Jacob MP
J Pathol; 2000 Sep; 192(1):105-12. PubMed ID: 10951407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]